scanX
Aurobindo Pharma
add_icon

Aurobindo Pharma

1,500.50
-11.30
(-0.75%)
Market Cap
87,149.28 Cr
PE Ratio
25.19
Volume
9,39,496.00
Day High - Low
1,525.00 - 1,491.60
52W High-Low
1,528.00 - 1,016.10
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
87,149.28 Cr
EPS
59.81
PE Ratio
25.19
PB Ratio
2.51
Book Value
603.32
EBITDA
7,204.60
Dividend Yield
0.00 %
Industry
Healthcare
Sector
Pharmaceuticals
Return on Equity
10.67
Debt to Equity
0.24
Analyst Rating and Forecast
- By Refinitiv from26 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+80.77 %
+80.77 %
Hold
Hold+3.85 %
+3.85 %
Sell
Sell+15.38 %
+15.38 %
Forecast For
Actual

Company News

View All News
Caret
negative
Telangana HC Dismisses Aurobindo Promoters' Writ Petition2 days ago
The Hon'ble High Court of Telangana dismissed a writ petition filed by Aurobindo Pharma promoters challenging a SEBI directive to deposit Rs. 6.53 crores in profits into IPEF.
positive
CuraTeQ Biologics Gets CDSCO Nod for Bevacizumab Biosimilar2 days ago
Aurobindo Pharma's subsidiary CuraTeQ Biologics receives CDSCO marketing authorisation (Form CT 23) for Bevqolva®, its bevacizumab biosimilar.
neutral
Aurobindo Pharma: ₹45.37 Cr NSE Block Trade5 days ago
Aurobindo Pharma sees a block trade of ~3,03,451 shares on NSE at ₹1,495.10 per share, aggregating to ₹45.37 crores.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,905.80
#1 4,57,265.26
41.18
#1 54,729.00
9.71
#1 10,980
16.07
67.81
Divis Laboratories
6,835.00
1,81,447.77
72.40
9,712.00
18.67
2,191
-1.02
66.76
Torrent Pharmaceuticals
4,393.70
1,48,702.77
65.64
11,539.40
6.99
1,911
26.24
57.60
Cipla
1,426.20
1,15,205.68
29.94
27,711.70
-2.46
3,783
-55.32
68.41
Dr Reddys Laboratories
1,331.20
1,11,107.68
26.84
33,593.30
-0.44
3,998
-86.05
58.65
Mankind Pharma
2,495.70
1,03,023.76
57.32
12,744.20
20.90
2,007
7.65
72.21
Lupin
2,252.40
1,02,944.41
#1 19.41
27,487.50
19.98
5,345
#1 87.72
43.67
Zydus Life Science
991.10
99,727.85
20.25
23,511.00
18.55
4,615
-0.32
63.02
Aurobindo Pharma
1,500.50
#9 87,149.28
#3 25.19
#3 32,345.60
#7 9.43
#6 3,484
#6 7.59
69.63
Laurus Labs
1,327.30
71,655.16
80.32
6,812.90
#1 21.03
884
21.18
80.55
Growth Rate
Revenue Growth
9.43 %
Net Income Growth
9.93 %
Cash Flow Change
61.21 %
ROE
0.47 %
ROCE
10.77 %
EBITDA Margin (Avg.)
2.86 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Revenue
3,151
3,272
3,324
3,450
3,710
3,728
3,742
3,871
3,625
3,645
4,366
4,302
4,033
4,226
4,694
5,242
5,234
5,377
5,539
5,830
6,108
5,951
6,432
9,300
6,071
5,802
5,987
6,089
5,844
6,218
5,731
6,481
6,514
6,907
7,339
7,434
7,628
7,679
7,783
8,052
8,516
7,899
8,359
8,793
Expenses
2,506
2,574
2,586
2,688
2,885
2,878
2,847
3,011
2,920
2,845
3,319
3,311
3,261
3,539
3,792
4,208
4,271
4,311
4,473
4,701
4,862
4,679
5,071
5,011
4,735
4,502
4,766
4,993
5,002
5,303
4,950
5,453
5,477
5,772
5,846
5,753
6,042
5,949
6,230
6,401
6,622
6,265
6,608
6,938
EBITDA
645
698
738
762
825
851
895
860
704
800
1,047
992
772
687
902
1,033
963
1,066
1,066
1,130
1,247
1,271
1,361
4,290
1,335
1,300
1,220
1,096
842
914
781
1,027
1,037
1,135
1,493
1,681
1,585
1,730
1,553
1,652
1,894
1,634
1,752
1,855
Operating Profit %
20 %
21 %
22 %
22 %
21 %
22 %
23 %
22 %
18 %
21 %
24 %
22 %
18 %
15 %
19 %
19 %
18 %
20 %
19 %
19 %
20 %
20 %
20 %
21 %
21 %
21 %
19 %
17 %
14 %
14 %
13 %
15 %
14 %
15 %
18 %
21 %
19 %
20 %
19 %
19 %
21 %
20 %
20 %
19 %
Depreciation
85
89
93
99
111
106
110
111
100
131
132
138
157
155
164
163
187
241
243
250
232
256
257
277
266
280
294
299
254
280
298
321
346
327
418
423
354
404
382
419
444
406
429
465
Interest
21
31
68
9
25
21
18
14
14
17
17
19
25
30
35
48
50
50
41
37
32
21
16
20
18
13
10
16
9
15
25
45
56
57
68
76
89
111
113
119
115
98
95
93
Profit Before Tax
557
634
631
717
761
786
830
796
649
709
979
902
651
571
787
917
816
863
864
938
1,078
1,084
1,193
4,005
1,061
1,018
968
794
594
679
523
680
730
812
1,076
1,262
1,230
1,324
1,208
1,200
1,335
1,207
1,276
1,339
Tax
153
162
178
173
206
201
224
218
117
191
198
307
122
116
175
205
231
228
224
233
229
301
386
1,058
260
248
271
190
18
159
113
189
224
242
324
323
323
406
391
354
432
383
428
429
Net Profit
403
472
453
545
555
585
606
579
532
518
781
595
529
456
611
712
585
636
640
705
849
783
807
2,948
801
770
697
604
576
520
410
491
506
570
752
940
907
918
817
846
903
824
848
910
EPS in ₹
13.84
16.18
7.77
9.32
9.49
9.99
10.41
9.88
9.10
8.85
13.33
10.16
9.02
7.78
10.44
12.15
9.99
10.85
10.92
12.04
14.50
13.32
13.78
50.31
13.67
13.14
11.89
10.32
9.84
8.88
6.99
8.38
8.64
9.74
12.83
16.04
15.51
15.69
14.00
14.56
15.56
14.20
14.61
15.67
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
12,915
15,920
16,249
21,101
26,454
28,928
33,854
33,922
39,890
45,072
49,785
Fixed Assets
3,706
4,180
4,834
6,521
8,475
9,397
9,374
10,532
11,024
14,493
14,794
Current Assets
8,299
10,294
9,206
12,178
15,332
16,413
19,824
18,123
21,460
23,772
27,163
Capital Work in Progress
420
848
1,458
1,583
1,669
1,986
3,062
3,747
5,390
3,869
4,900
Investments
20
123
246
312
360
555
591
997
543
372
252
Other Assets
8,770
10,769
9,712
12,686
15,951
16,991
20,828
18,645
22,934
26,338
29,839
Total Equity & Liabilities
12,915
15,920
16,249
21,101
26,454
28,928
33,854
33,922
39,890
45,072
49,785
Current Liabilities
6,136
7,840
6,606
8,666
12,021
11,385
10,665
8,156
11,494
12,199
14,682
Non Current Liabilities
1,596
790
270
753
541
718
1,260
1,192
1,544
3,022
2,456
Total Equity
5,182
7,290
9,374
11,682
13,892
16,825
21,929
24,574
26,852
29,851
32,647
Reserve & Surplus
5,127
7,229
9,313
11,622
13,832
16,766
21,871
24,517
26,781
29,784
32,595
Share Capital
29
59
59
59
59
59
59
59
59
59
58
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
313
340
-424
892
666
871
2,561
-1,164
230
-1,007
2,178
Investing Activities
-1,017
-1,446
-1,787
-1,927
-2,904
-1,563
597
-3,211
-3,971
-4,242
-1,866
Operating Activities
1,237
1,420
3,279
1,955
1,651
4,381
3,329
5,017
2,387
2,435
3,925
Financing Activities
93
365
-1,915
864
1,919
-1,947
-1,365
-2,969
1,814
800
120
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Promoter
51.94 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.80 %
51.82 %
51.82 %
51.82 %
51.82 %
51.82 %
51.82 %
51.82 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.00 %
0.00 %
0.00 %
0.00 %
18.02 %
16.73 %
16.59 %
16.29 %
15.33 %
14.37 %
14.21 %
13.94 %
15.24 %
DIIs
10.99 %
12.72 %
13.82 %
15.11 %
15.83 %
15.58 %
16.23 %
14.89 %
15.08 %
15.73 %
17.94 %
20.23 %
23.28 %
24.77 %
25.13 %
25.20 %
26.23 %
26.93 %
27.60 %
27.68 %
25.87 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
8.71 %
8.54 %
9.60 %
8.99 %
8.37 %
8.80 %
8.65 %
9.42 %
8.54 %
7.01 %
6.15 %
5.64 %
5.52 %
5.47 %
5.33 %
5.52 %
5.47 %
5.67 %
5.25 %
5.36 %
5.74 %
Others
28.36 %
26.91 %
24.74 %
24.07 %
23.97 %
23.79 %
23.29 %
23.85 %
24.54 %
25.42 %
24.07 %
22.29 %
1.36 %
1.23 %
1.13 %
1.17 %
1.15 %
1.20 %
1.13 %
1.19 %
1.34 %
No of Share Holders
2,32,634
2,43,315
3,29,940
3,41,568
3,38,639
3,59,684
3,58,459
3,69,828
3,43,617
2,93,214
2,59,638
2,41,944
2,44,575
2,38,622
2,48,488
2,57,962
2,69,323
2,72,208
2,47,662
2,36,859
2,41,298

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 3.2 2.5 2.5 3 4 9 7.5 4.5 0.00 0.00
Dividend Yield (%) 0.57 0.32 0.61 0.34 0.6 1.77 0.69 0.39 0.00 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
21 May 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 21 May 2026 1,485.90 1,511.30
23 Feb 2021 DIVIDEND Dividend
₹ 1.50 /share
 22 Feb 2021 959.45 858.10
30 Aug 2021 DIVIDEND Dividend
₹ 1.50 /share
 27 Aug 2021 856.50 709.95
18 Nov 2021 DIVIDEND Dividend
₹ 1.50 /share
 17 Nov 2021 690.05 666.55
21 Feb 2022 DIVIDEND Dividend
₹ 1.50 /share
 18 Feb 2022 650.05 656.80
07 Jun 2022 DIVIDEND Dividend
₹ 4.50 /share
 06 Jun 2022 529.70 522.50
17 Feb 2023 DIVIDEND Dividend
₹ 3.00 /share
 17 Feb 2023 445.05 479.90
20 Nov 2023 DIVIDEND Dividend
₹ 3.00 /share
 20 Nov 2023 936.40 1,007.35
20 Feb 2024 DIVIDEND Dividend
₹ 1.50 /share
 20 Feb 2024 1,002.00 1,040.50
05 Aug 2024 BUYBACK Buyback
1460
 30 Jul 2024 1,479.35 1,443.65
29 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 29 Aug 2024 1,404.35 1,564.20
09 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 09 Nov 2024 1,396.00 1,327.55
06 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 06 Feb 2025 1,156.60 1,191.75
26 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 26 May 2025 1,216.90 1,197.10
04 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 04 Aug 2025 1,101.40 1,079.80
08 Aug 2025 DIVIDEND Dividend
₹ 4.00 /share
 08 Aug 2025 1,079.80 1,069.60
10 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 10 Sept 2025 1,052.90 1,044.05
05 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 05 Nov 2025 1,098.95 1,151.00
09 Feb 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 09 Feb 2026 1,150.55 1,191.00
23 Apr 2026 BUYBACK Buyback
1475
 17 Apr 2026 1,421.30 1,420.90

Announcements

Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 20152 days ago
Curateq Biologics Receives CDSCO Marketing Authorisation (Form CT 23) For Bevqolva® (Bevacizumab Biosimilar)2 days ago
Announcement under Regulation 30 (LODR)-Closure of Buy Back3 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation4 days ago
Board Meeting Intimation for Consider And Approve Inter Alia The Standalone & Consolidated Audited Financial Results Of The Company For The Fourth Quarter And Financial Year Ended March 31 20266 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication10 days ago
US FDA Classification Of Unit-VII Of Aurobindo Pharma Limited As Voluntary Action Indicated (VAI)May 06, 2026
Intimation Of Resignation Of Dr. Sanjay Chaturvedi CEO Of Apitoria Pharma Private Limited Wholly Owned Subsidiary Of The CompanyMay 04, 2026
Curateq Biologics Secures Health Canada NOC For Bevqolvaâ„¢ Bevacizumab BiosimilarMay 01, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementApr 30, 2026
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 24, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 22, 2026
Letter Of Offer For Buyback Of Up To 5423728 Fully Paid-Up Equity Shares Of The CompanyApr 21, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 17, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 17, 2026
Expanding Existing CMO Operations With Merck Sharpe & Dohme Singapore Trading Pte. Ltd By Theranym Biologics Private Limited A Subsidiary Of The Company .Apr 15, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 09, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 08, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 08, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 07, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 07, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 06, 2026
Intimation Of Record Date For BuybackApr 06, 2026
Transfer Of Companys Domestic Branded Pharmaceutical Formulation Business To Auropharm Limited A Wholly Owned Subsidiary Of The Company.Apr 06, 2026
Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors - Buyback Of SharesApr 06, 2026
Board Meeting Intimation for To Consider Inter Alia A Proposal For Buyback Of The Fully Paid-Up Equity Shares Of The CompanyMar 31, 2026
Update On Solar Power Purchase Agreement And Acquisition Upto 26% Stake In Swarnaakshu Solar Power Private Limited.Mar 30, 2026
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 30, 2026
Entry Into Marketing And Distribution Agreement For Biosimilars In EU Territories By Curateq Biologics Private LimitedMar 25, 2026
Closure of Trading WindowMar 23, 2026
Classification Of Unit-V Of Apitoria Pharma Limited A Wholly Owned Subsidiary Of The Company As VAI By The US FDAMar 20, 2026
Classification Of Unit-II Of Eugia Pharma Specialities Limited A Wholly Owned Subsidiary Of The Company As OAI By The US FDAMar 17, 2026
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 13, 2026
Classification Of Unit-IV Of APL Healthcare Limited A Wholly Owned Subsidiary Of The Company As VAI By The US FDA - Reg.Mar 12, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 11, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 11, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 09, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 04, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 02, 2026
Clarification On Media Report Aurobindo PharmaS P Sarath Chandra Reddy Acquitted In Delhi Liquor Scam Case. Mar 02, 2026
Clarification sought from Aurobindo Pharma LtdFeb 27, 2026
Completion Of US FDA Inspection At Unit I Of Eugia Pharma Specialities LtdFeb 27, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 26, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 25, 2026
Announcement under Regulation 30 (LODR)-AcquisitionFeb 24, 2026
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 24, 2026
Intimation Of Orders Passed By The Goods & Services Tax DepartmentFeb 19, 2026
Clarification On News Item Appearing In Https://Www.Ndtvprofit.Com/"Feb 18, 2026
Clarification sought from Aurobindo Pharma LtdFeb 18, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 16, 2026

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Bandhan Multi-Factor Fund Direct-Growth
3.55%
162141
3.34%
-0.21%
The Wealth Company Flexi Cap Fund Direct-Growth
0.98%
-19900
-1.42%
-1.31%
The Wealth Company Arbitrage Fund Direct-Growth
0.00%
-17050
-1.45%
-1.18%
TRUSTMF Multi Cap Fund Direct-Growth
0.53%
-16033
-0.61%
0.53%
Old Bridge Flexi Cap Fund Direct-Growth
3.15%
14000
0.79%
3.15%
ITI Business Cycle Fund Direct-Growth
1.17%
8694
1.17%
1.17%
Unifi Dynamic Asset Allocation Fund Direct-Growth
0.25%
-1650
-0.01%
-0.06%
Tata Nifty Midcap 150 Index Fund Direct-Growth
1.00%
1560
-0.05%
0.10%
Sundaram Multi-Factor Fund Direct-Growth
1.33%
-1437
-0.06%
0.20%
Edelweiss Nifty LargeMidcap250 Plus 8-13 Yr G-Sec 70:30 Index Fund Direct-Growth
0.35%
1075
0.35%
0.35%
Franklin India Multi-Factor Fund Direct-Growth
0.78%
992
-0.03%
0.08%
JioBlackRock Nifty Midcap 150 Index Fund Direct-Growth
0.99%
-750
-0.06%
0.09%
DSP Nifty Healthcare Index Fund Direct-Growth
3.84%
423
0.06%
0.44%
UTI Nifty500 Shariah Index Fund Direct-Growth
0.69%
408
-0.01%
0.09%
Zerodha Nifty LargeMidcap250 Plus 8-13 Yr G-Sec 70:30 Index Fund Direct-Growth
0.37%
398
0.37%
0.37%
Zerodha Nifty MidSmallcap400 50:50 Index Fund Direct-Growth
0.50%
284
0.50%
0.50%
JioBlackRock Sector Rotation Fund Direct-Growth
0.19%
260
0.00%
0.03%
Kotak Nifty Midcap 150 Index Fund Direct-Growth
1.00%
233
-0.05%
0.10%
Nippon India Nifty India Manufacturing Index Fund Direct-Growth
1.00%
127
-0.04%
0.12%
DSP Nifty Midcap 150 Index Fund Direct-Growth
0.99%
99
-0.05%
0.09%
Groww Nifty Midcap 150 Index Fund Direct-Growth
0.99%
37
-0.06%
0.09%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.19%
32
-0.01%
0.03%
Navi Nifty MidSmallcap 400 Index Fund Direct-Growth
0.65%
21
-0.04%
0.05%
DSP Nifty 500 Index Fund Direct-Growth
0.20%
12
0.00%
0.03%
Mahindra Manulife Multi Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%

Technical Indicators

RSI(14)
Neutral
73.83
ATR(14)
Less Volatile
34.57
STOCH(9,6)
Overbought
86.05
STOCH RSI(14)
Overbought
96.79
MACD(12,26)
Bullish
3.93
ADX(14)
Strong Trend
28.04
UO(9)
Bearish
44.12
ROC(12)
Uptrend And Accelerating
6.27
WillR(14)
Overbought
-10.06
Bearish
5
Neutral
1
Bullish
3

About Aurobindo Pharma

Aurobindo Pharma Limited (APL) is an Indian pharmaceutical company founded in 1986. It manufactures and markets active pharmaceutical ingredients, generic formulations, and branded pharmaceuticals globally. APL specializes in various therapeutic areas including antibiotics, antiretrovirals, cardiovascular, central nervous system, and gastroenterological products. The company operates 24 manufacturing plants worldwide and has...more
Website
https://www.aurobindo.com
Chairperson NameM R Kumar
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

© 2025 - 2026 Raise Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104